Division of Hematologic Malignancies & Hematopoietic Stem Cell Transplantation

Designated a center of excellence in cancer care and research, Thomas Jefferson University Hospitals' Kimmel Cancer Center treats patients with hematological malignancies, the most common forms of which are leukemia (acute and chronic myelogenous and lymphocytic), Hodgkins and non-Hodgkins lymphoma and multiple myeloma. 

These cancers may arise from the bone marrow, lymph nodes or extra-nodal locations such as the stomach, brain, testes and orbit.

The Kimmel Cancer Center brings together a multidisciplinary team of medical oncologists, radiation oncologists, pathologists and radiologists, who collaborate on evaluation and diagnosis and guide the patient through the most appropriate course of treatment. Chemotherapy is the mainstay of treatment for these cancers, but radiation plays an important role in treating certain types of lymphomas.

The bone marrow transplant team at Jefferson meets the requirements of the Foundation for the Accreditation of Cellular Therapy (FACT) for bone marrow and tissue transplantation. Specialists in the program are pioneering efforts to expand the pool of potential donors and to reduce complications of transplant procedures, such as graft-versus-host disease (GVHD).

S. Onder Alpdogan, MD

Xia Bi, MD, MS

Adam Binder, MD 

Joanne Filicko-O'Hara, MD

Usama Gergis, MD, MBA

Margaret T. Kasner, MD

Gina Keiffer, MD

Ubaldo Martinez-Outschoorn, MD

Pierluigi Porcu, MD 

Lindsey Wilde, MD is focused on growing her academic career as a clinical researcher in acute leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. Since finishing her fellowship in 2018, Dr. Wilde has built a clinical trial portfolio as an investigator and have been involved in all aspects of designing and implementing therapeutic trials, including securing funding, applying for an IND, managing a clinical research team, and collaborating with laboratory colleagues. She is also interested in improving care delivery to patients with hematologic malignancies and have collaborated on several inter-disciplinary projects focusing on novel strategies to improve resource utilization and medication adherence. Dr. Wilde continues to be involved in medical education at the undergraduate and graduate levels and serves as the Program Director for the Hematology/Oncology Fellowship Program.